Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer - Archive ouverte HAL Access content directly
Journal Articles CPT: Pharmacometrics and Systems Pharmacology Year : 2019

Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer

(1) , (2) , (2) , (3) , (4) , (5, 6) , (1)
1
2
3
4
5
6

Abstract

Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) is a first line therapeutic for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BE V- PEM/CIS has a narrow therapeutic window. Therefore, it is an attractive target for administration schedule optimization. The present study leverages our previous work on BEV-PEM/CIS pharmacodynamic modeling in NSCLC-bearing mice to estimate the optimal gap in the scheduling of sequential BEV-PEM/CIS. We predicted the optimal gap in BEV-PEM/CIS dosing to be 2.0 days in mice and 1.2 days in humans. Our simulationssuggest that the efficacy loss in scheduling BEV-PEM/CIS at too great of a gap is much less than the efficacy loss in scheduling BEV-PEM/CIS at too short of a gap.
Fichier principal
Vignette du fichier
19_schneider.pdf (1.19 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02109335 , version 1 (24-04-2019)

Identifiers

Cite

Benjamin K Schneider, Arnaud Boyer, Joseph Ciccolini, Fabrice Barlesi, Kenneth Wang, et al.. Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2019, ⟨10.1002/psp4.12415⟩. ⟨hal-02109335⟩
133 View
146 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More